Control of Interleukin-2 Gene Transcription: A Paradigm for Inducible, Tissue-Specific Gene Expression

Vitamins and Hormones

Volumn 74, Issue , 2006, Pages 105-145

  Bunting, Karen ^a   Wang, Jun ^a   Shannon, M Frances ^a  

^a Biology and Environment   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; T LYMPHOCYTE RECEPTOR;

ANIMAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; INTERLEUKIN-2; T-CELL ANTIGEN RECEPTOR SPECIFICITY; TRANSCRIPTION, GENETIC;

EID: 33947723986     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(06)74005-5     Document Type: Review

References (215)

1. Abraham C., and Miller J. Molecular mechanisms of IL-2 gene regulation following costimulation through LFA-1. J. Immunol. 167 (2001) 5193-5201
2. Adachi S., and Rothenberg E.V. Cell-type-specific epigenetic marking of the IL2 gene at a distal cis-regulatory region in competent, nontranscribing T-cells. Nucleic Acids Res. 33 (2005) 3200-3210
3. Attema J.L., Reeves R., Murray V., Levichkin I., Temple M.D., Tremethick D.J., and Shannon M.F. The human IL-2 gene promoter can assemble a positioned nucleosome that becomes remodeled upon T cell activation. J. Immunol. 169 (2002) 2466-2476
4. Avots A., Escher C., Muller-Deubert S., Neumann M., and Serfling E. The interplay between lymphoid-specific and ubiquitous transcription factors controls the expression of interleukin 2 gene in T lymphocytes. Immunobiology 193 (1995) 254-258
5. Avots A., Hoffmeyer A., Flory E., Cimanis A., Rapp U.R., and Serfling E. GABP factors bind to a distal interleukin 2 (IL-2) enhancer and contribute to c-Raf-mediated increase in IL-2 induction. Mol. Cell. Biol. 17 (1997) 4381-4389
6. Barton K., Muthusamy N., Chanyangam M., Fischer C., Clendenin C., and Leiden J.M. Defective thymocyte proliferation and IL-2 production in transgenic mice expressing a dominant-negative form of CREB. Nature 379 (1996) 81-85
7. Bayer A.L., Yu A., Adeegbe D., and Malek T.R. Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J. Exp. Med. 201 (2005) 769-777
8. Ben Aribia M.H., Leroy E., Lantz O., Metivier D., Autran B., Charpentier B., Hercend T., and Senik A. rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: Synergistic effects of IL 1 and IL 2. J. Immunol. 139 (1987) 443-451
9. Beverly B., Kang S.M., Lenardo M.J., and Schwartz R.H. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int. Immunol. 4 (1992) 661-671
10. Bjorndahl J.M., Sung S.S., Hansen J.A., and Fu S.M. Human T cell activation: Differential response to anti-CD28 as compared to anti-CD3 monoclonal antibodies. Eur. J. Immunol. 19 (1989) 881-887
11. Bodor J., and Habener J.F. Role of transcriptional repressor ICER in cyclic AMP-mediated attenuation of cytokine gene expression in human thymocytes. J. Biol. Chem. 273 (1998) 9544-9551
12. Bodor J., Spetz A.L., Strominger J.L., and Habener J.F. cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc. Natl. Acad. Sci. USA 93 (1996) 3536-3541
13. Bodor J., Bodorova J., and Gress R.E. Suppression of T cell function: A potential role for transcriptional repressor ICER. J. Leukoc. Biol. 67 (2000) 774-779
14. Bodor J., Feigenbaum L., Bodorova J., Bare C., Reitz Jr. M.S., and Gress R.E. Suppression of T-cell responsiveness by inducible cAMP early repressor (ICER). J. Leukoc. Biol. 69 (2001) 1053-1059
15. Boeger H., Griesenbeck J., Strattan J.S., and Kornberg R.D. Nucleosomes unfold completely at a transcriptionally active promoter. Mol. Cell 11 (2003) 1587-1598
16. Boise L.H., Petryniak B., Mao X., June C.H., Wang C.Y., Lindsten T., Bravo R., Kovary K., Leiden J.M., and Thompson C.B. The NFAT-1 DNA binding complex in activated T cells contains Fra-1 and JunB. Mol. Cell. Biol. 13 (1993) 1911-1919
17. Boumpas D.T., Anastassiou E.D., Older S.A., Tsokos G.C., Nelson D.L., and Balow J.E. Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J. Clin. Invest. 87 (1991) 1739-1747
18. Bream J.H., Curiel R.E., Yu C.R., Egwuagu C.E., Grusby M.J., Aune T.M., and Young H.A. IL-4 synergistically enhances both IL-2- and IL-12-induced IFN-gamma expression in murine NK cells. Blood 102 (2003) 207-214
19. Briegel K., Hentsch B., Pfeuffer I., and Serfling E. One base pair change abolishes the T cell-restricted activity of a kB-like proto-enhancer element from the interleukin 2 promoter. Nucleic Acids Res. 19 (1991) 5929-5936
20. Bruniquel D., and Schwartz R.H. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat. Immunol. 4 (2003) 235-240
21. Brunvand M.W., Schmidt A., and Siebenlist U. Nuclear factors interacting with the mitogen-responsive regulatory region of the interleukin-2 gene. J. Biol. Chem. 263 (1988) 18904-18910
22. Brunvand M.W., Krumm A., and Groudine M. In vivo footprinting of the human IL-2 gene reveals a nuclear factor bound to the transcription start site in T cells. Nucleic Acids Res. 21 (1993) 4824-4829
23. Bryan R.G., Li Y., Lai J.H., Van M., Rice N.R., Rich R.R., and Tan T.H. Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells. Mol. Cell. Biol. 14 (1994) 7933-7942
24. Butscher W.G., Powers C., Olive M., Vinson C., and Gardner K. Coordinate transactivation of the interleukin-2 CD28 response element by c-Rel and ATF-1/CREB2. J. Biol. Chem. 273 (1998) 552-560
25. Butscher W.G., Haggerty C.M., Chaudhry S., and Gardner K. Targeting of p300 to the interleukin-2 promoter via CREB-Rel cross-talk during mitogen and oncogenic molecular signaling in activated T-cells. J. Biol. Chem. 276 (2001) 27647-27656
26. Chen D., and Rothenberg E.V. Molecular basis for developmental changes in interleukin-2 gene inducibility. Mol. Cell. Biol. 13 (1993) 228-237
27. Chen X., Wang J., Woltring D., Gerondakis S., and Shannon M.F. Histone dynamics on the interleukin-2 gene in response to T-cell activation. Mol. Cell. Biol. 25 (2005) 3209-3219
28. Chirathaworn C., Kohlmeier J.E., Tibbetts S.A., Rumsey L.M., Chan M.A., and Benedict S.H. Stimulation through intercellular adhesion molecule-1 provides a second signal for T cell activation. J. Immunol. 168 (2002) 5530-5537
29. Chow C.W., Rincon M., and Davis R.J. Requirement for transcription factor NFAT in interleukin-2 expression. Mol. Cell. Biol. 19 (1999) 2300-2307
30. Clerici M., Galli M., Bosis S., Gervasoni C., Moroni M., and Norbiato G. Immunoendocrinologic abnormalities in human immunodeficiency virus infection. Ann. N. Y. Acad. Sci. 917 (2000) 956-961
31. Corcoran L.M., and Karvelas M. Oct-2 is required early in T cell-independent B cell activation for G1 progression and for proliferation. Immunity 1 (1994) 635-645
32. Costello R., Lipcey C., Algarte M., Cerdan C., Baeuerle P.A., Olive D., and Imbert J. Activation of primary human T-lymphocytes through CD2 plus CD28 adhesion molecules induces long-term nuclear expression of NF-kappa B. Cell Growth Differ. 4 (1993) 329-339
33. Coyle A.J., and Gutierrez-Ramos J.C. The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function. Nat. Immunol. 2 (2001) 203-209
34. Crabtree G.R. Contingent genetic regulatory events in T lymphocyte activation. Science 243 (1989) 355-361
35. Crispin J.C., and Alcocer-Varela J. Interleukin-2 and systemic lupus erythematosus-fifteen years later. Lupus 7 (1998) 214-222
36. Curtiss V.E., Smilde R., and McGuire K.L. Requirements for interleukin 2 promoter transactivation by the Tax protein of human T-cell leukemia virus type 1. Mol. Cell. Biol. 16 (1996) 3567-3575
37. D'Ambrosio D., Trotta R., Vacca A., Frati L., Santoni A., Gulino A., and Testi R. Transcriptional regulation of interleukin-2 gene expression by CD69-generated signals. Eur. J. Immunol. 23 (1993) 2993-2997
38. De Cesare D., Fimia G.M., and Sassone-Corsi P. Signaling routes to CREM and CREB: Plasticity in transcriptional activation. Trends Biochem. Sci. 24 (1999) 281-285
39. de Grazia U., Felli M.P., Vacca A., Farina A.R., Maroder M., Cappabianca L., Meco D., Farina M., Screpanti I., Frati L., and Gulino A. Positive and negative regulation of the composite octamer motif of the interleukin 2 enhancer by AP-1, Oct-2, and retinoic acid receptor. J. Exp. Med. 180 (1994) 1485-1497
40. Daniel P.B., and Habener J.F. Cyclical alternative exon splicing of transcription factor cyclic adenosine monophosphate response element-binding protein (CREB) messenger ribonucleic acid during rat spermatogenesis. Endocrinology 139 (1998) 3721-3729
41. Decker E.L., Skerka C., and Zipfel P.F. The early growth response protein (EGR-1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells. J. Biol. Chem. 273 (1998) 26923-26930
42. Devos R., Plaetinck G., Cheroutre H., Simons G., Degrave W., Tavernier J., Remaut E., and Fiers W. Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res. 11 (1983) 4307-4323
43. Diehn M., Alizadeh A.A., Rando O.J., Liu C.L., Stankunas K., Botstein D., Crabtree G.R., and Brown P.O. Genomic expression programs and the integration of the CD28 costimulatory signal in T cell activation. Proc. Natl. Acad. Sci. USA 99 (2002) 11796-11801
44. Dubey C., Croft M., and Swain S.L. Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response. J. Immunol. 155 (1995) 45-57
45. Durand D.B., Bush M.R., Morgan J.G., Weiss A., and Crabtree G.R. A 275 basepair fragment at the 5′ end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the T cell antigen receptor. J. Exp. Med. 165 (1987) 395-407
46. Durand D.B., Shaw J.P., Bush M.R., Replogle R.E., Belagaje R., and Crabtree G.R. Characterization of antigen receptor response elements within the interleukin-2 enhancer. Mol. Cell. Biol. 8 (1988) 1715-1724
47. Eberharter A., and Becker P.B. Histone acetylation: A switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep. 3 (2002) 224-229
48. Eerligh P., Koeleman B.P., Dudbridge F., Jan Bruining G., Roep B.O., and Giphart M.J. Functional genetic polymorphisms in cytokines and metabolic genes as additional genetic markers for susceptibility to develop type 1 diabetes. Genes Immun. 5 (2004) 36-40
49. Egen J.G., and Allison J.P. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16 (2002) 23-35
50. Emmel E.A., Verweij C.L., Durand D.B., Higgins K.M., Lacy E., and Crabtree G.R. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation. Science 246 (1989) 1617-1620
51. Erlanson D.A., Chytil M., and Verdine G.L. The leucine zipper domain controls the orientation of AP-1 in the NFAT.AP-1.DNA complex. Chem. Biol. 3 (1996) 981-991
52. Favero J., and Lafont V. Effector pathways regulating T cell activation. Biochem. Pharmacol. 56 (1998) 1539-1547
53. Ferreri K., Gill G., and Montminy M. The cAMP-regulated transcription factor CREB interacts with a component of the TFIID complex. Proc. Natl. Acad. Sci. USA 91 (1994) 1210-1213
54. Finch R.J., Fields P.E., and Greenberg P.D. A transcriptional block in the IL-2 promoter at the -150 AP-1 site in effector CD8+ T cells. J. Immunol. 166 (2001) 6530-6536
55. Fortin J.F., Barat C., Beausejour Y., Barbeau B., and Tremblay M.J. Hyper-responsiveness to stimulation of human immunodeficiency virus-infected CD4+ T cells requires Nef and Tat virus gene products and results from higher NFAT, NF-kappaB, and AP-1 induction. J. Biol. Chem. 279 (2004) 39520-39531
56. Foulkes N.S., Laoide B.M., Schlotter F., and Sassone-Corsi P. Transcriptional antagonist cAMP-responsive element modulator (CREM) down-regulates c-fos cAMP-induced expression. Proc. Natl. Acad. Sci. USA 88 (1991) 5448-5452
57. Fraser J.D., and Weiss A. Regulation of T-cell lymphokine gene transcription by the accessory molecule CD28. Mol. Cell. Biol. 12 (1992) 4357-4363
58. Fujita T., Takaoka C., Matsui H., and Taniguchi T. Structure of the human interleukin 2 gene. Proc. Natl. Acad. Sci. USA 80 (1983) 7437-7441
59. Fujita T., Shibuya H., Ohashi T., Yamanishi K., and Taniguchi T. Regulation of human interleukin-2 gene: Functional DNA sequences in the 5′ flanking region for the gene expression in activated T lymphocytes. Cell 46 (1986) 401-405
60. Gaffen S.L., and Liu K.D. Overview of interleukin-2 function, production and clinical applications. Cytokine 28 (2004) 109-123
61. Garcia-Rodriguez C., and Rao A. Nuclear factor of activated T cells (NFAT)-dependent transactivation regulated by the coactivators p300/CREB-binding protein (CBP). J. Exp. Med. 187 (1998) 2031-2036
62. Garrity P.A., Chen D., Rothenberg E.V., and Wold B.J. Interleukin-2 transcription is regulated in vivo at the level of coordinated binding of both constitutive and regulated factors. Mol. Cell. Biol. 14 (1994) 2159-2169
63. Geist L.J., Monick M.M., Stinski M.F., and Hunninghake G.W. The immediate early genes of human cytomegalovirus upregulate expression of the interleukin-2 and interleukin-2 receptor genes. Am. J. Respir. Cell. Mol. Biol. 5 (1991) 292-296
64. Gerondakis S., Strasser A., Metcalf D., Grigoriadis G., Scheerlinck J.Y., and Grumont R.J. Rel-deficient T cells exhibit defects in production of interleukin 3 and granulocyte-macrophage colony-stimulating factor. Proc. Natl. Acad. Sci. USA 93 (1996) 3405-3409
65. Gesbert F., Moreau J.L., and Theze J. IL-2 responsiveness of CD4 and CD8 lymphocytes: Further investigations with human IL-2Rbeta transgenic mice. Int. Immunol. 17 (2005) 1093-1102
66. Ghosh P., Tan T.H., Rice N.R., Sica A., and Young H.A. The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65. Proc. Natl. Acad. Sci. USA 90 (1993) 1696-1700
67. Gonzalez G.A., and Montminy M.R. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59 (1989) 675-680
68. Granelli-Piperno A., and Nolan P. Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J. Immunol. 147 (1991) 2734-2739
69. Granucci F., Zanoni I., Feau S., and Ricciardi-Castagnoli P. Dendritic cell regulation of immune responses: A new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. 22 (2003) 2546-2551
70. Grossmann M., Metcalf D., Merryfull J., Beg A., Baltimore D., and Gerondakis S. The combined absence of the transcription factors Rel and RelA leads to multiple hemopoietic cell defects. Proc. Natl. Acad. Sci. USA 96 (1999) 11848-11853
71. Harant H., and Lindley I.J. Negative cross-talk between the human orphan nuclear receptor Nur77/NAK-1/TR3 and nuclear factor-kappaB. Nucleic Acids Res. 32 (2004) 5280-5290
72. Harris J.E., Bishop K.D., Phillips N.E., Mordes J.P., Greiner D.L., Rossini A.A., and Czech M.P. Early growth response gene-2, a zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells. J. Immunol. 173 (2004) 7331-7338
73. Heisel O., and Keown P. Alterations in transcription factor binding at the IL-2 promoter region in anergized human CD4+ T lymphocytes. Transplantation 72 (2001) 1416-1422
74. Hendrich B., and Tweedie S. The methyl-CpG binding domain and the evolving role of DNA methylation in animals. Trends Genet. 19 (2003) 269-277
75. Hentsch B., Mouzaki A., Pfeuffer I., Rungger D., and Serfling E. The weak, fine-tuned binding of ubiquitous transcription factors to the Il-2 enhancer contributes to its T cell-restricted activity. Nucleic Acids Res. 20 (1992) 2657-2665
76. Himes S.R., Coles L.S., Reeves R., and Shannon M.F. High mobility group protein I(Y) is required for function and for c-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. Immunity 5 (1996) 479-489
77. Hoeffler J.P., Deutsch P.J., Lin J., and Habener J.F. Distinct adenosine 3′, 5′-monophosphate and phorbol ester-responsive signal transduction pathways converge at the level of transcriptional activation by the interactions of DNA-binding proteins. Mol. Endocrinol. 3 (1989) 868-880
78. Holbrook N.J., Smith K.A., Fornace Jr. A.J., Comeau C.M., Wiskocil R.L., and Crabtree G.R. T-cell growth factor: Complete nucleotide sequence and organization of the gene in normal and malignant cells. Proc. Natl. Acad. Sci. USA 81 (1984) 1634-1638
79. Hollander G.A. On the stochastic regulation of interleukin-2 transcription. Semin. Immunol. 11 (1999) 357-367
80. Hollander G.A., Zuklys S., Morel C., Mizoguchi E., Mobisson K., Simpson S., Terhorst C., Wishart W., Golan D.E., Bhan A.K., and Burakoff S.J. Monoallelic expression of the interleukin-2 locus. Science 279 (1998) 2118-2121
81. Hughes C.C., and Pober J.S. Costimulation of peripheral blood T cell activation by human endothelial cells. Enhanced IL-2 transcription correlates with increased c-fos synthesis and increased Fos content of AP-1. J. Immunol. 150 (1993) 3148-3160
82. Hwang E.S., Hong J.H., and Glimcher L.H. IL-2 production in developing Th1 cells is regulated by heterodimerization of RelA and T-bet and requires T-bet serine residue 508. J. Exp. Med. 202 (2005) 1289-1300
83. Iacobelli M., Wachsman W., and McGuire K.L. Repression of IL-2 promoter activity by the novel basic leucine zipper p21SNFT protein. J. Immunol. 165 (2000) 860-868
84. Isakov N., and Altman A. Tumor promoters in conjunction with calcium ionophores mimic antigenic stimulation by reactivation of alloantigen-primed murine T lymphocytes. J. Immunol. 135 (1985) 3674-3680
85. Iwashima M. Kinetic perspectives of T cell antigen receptor signaling. A two-tier model for T cell full activation. Immunol. Rev. 191 (2003) 196-210
86. Jain J., Loh C., and Rao A. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 7 (1995) 333-342
87. Jain J., Valge-Archer V.E., and Rao A. Analysis of the AP-1 sites in the IL-2 promoter. J. Immunol. 148 (1992) 1240-1250
88. Jain J., Valge-Archer V.E., Sinskey A.J., and Rao A. The AP-1 site at -150 bp, but not the NF-kappa B site, is likely to represent the major target of protein kinase C in the interleukin 2 promoter. J. Exp. Med. 175 (1992) 853-862
89. Jain J., McCaffrey P.G., Valge-Archer V.E., and Rao A. Nuclear factor of activated T cells contains Fos and Jun. Nature 356 (1992) 801-804
90. Jhun B.S., Oh Y.T., Lee J.Y., Kong Y., Yoon K.S., Kim S.S., Baik H.H., Ha J., and Kang I. AICAR suppresses IL-2 expression through inhibition of GSK-3 phosphorylation and NF-AT activation in Jurkat T cells. Biochem. Biophys. Res. Commun. 332 (2005) 339-346
91. John S., Reeves R.B., Lin J.X., Child R., Leiden J.M., Thompson C.B., and Leonard W.J. Regulation of cell-type-specific interleukin-2 receptor alpha-chain gene expression: Potential role of physical interactions between Elf-1, HMG-I(Y), and NF-kappa B family proteins. Mol. Cell. Biol. 15 (1995) 1786-1796
92. Jonat C., Rahmsdorf H.J., Park K.K., Cato A.C., Gebel S., Ponta H., and Herrlich P. Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone. Cell 62 (1990) 1189-1204
93. Juang Y.T., Wang Y., Solomou E.E., Li Y., Mawrin C., Tenbrock K., Kyttaris V.C., and Tsokos G.C. Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. J. Clin. Invest. 115 (2005) 996-1005
94. Kamps M.P., Corcoran L., LeBowitz J.H., and Baltimore D. The promoter of the human interleukin-2 gene contains two octamer-binding sites and is partially activated by the expression of Oct-2. Mol. Cell. Biol. 10 (1990) 5464-5472
95. Kedzierska K., and Crowe S.M. Cytokines and HIV-1: Interactions and clinical implications. Antivir. Chem. Chemother. 12 (2001) 133-150
96. Kelso A. Cytokines: Principles and prospects. Immunol. Cell. Biol. 76 (1998) 300-317
97. Kneitz B., Herrmann T., Yonehara S., and Schimpl A. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur. J. Immunol. 25 (1995) 2572-2577
98. Kohm A.P., Podojil J.R., Williams J.S., McMahon J.S., and Miller S.D. CD28 regulates glucocorticoid-induced TNF receptor family-related gene expression on CD4+ T cells via IL-2-dependent mechanisms. Cell. Immunol. 235 (2005) 56-64
99. Koretzky G.A., and Myung P.S. Positive and negative regulation of T-cell activation by adaptor proteins. Nat. Rev. Immunol. 1 (2001) 95-107
100. Kumar P.P., Purbey P.K., Ravi D.S., Mitra D., and Galande S. Displacement of SATB1-bound histone deacetylase 1 corepressor by the human immunodeficiency virus type 1 transactivator induces expression of interleukin-2 and its receptor in T cells. Mol. Cell. Biol. 25 (2005) 1620-1633
101. Kyttaris V.C., Juang Y.T., Tenbrock K., Weinstein A., and Tsokos G.C. Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J. Immunol. 173 (2004) 3557-3563
102. Ledo F., Carrion A.M., Link W.A., Mellstrom B., and Naranjo J.R. DREAM-alphaCREM interaction via leucine-charged domains derepresses downstream regulatory element-dependent transcription. Mol. Cell. Biol. 20 (2000) 9120-9126
103. 2+-dependent block of CREB-CBP transcription by repressor DREAM. EMBO J. 21 (2002) 4583-4592
104. Li L., Godfrey W.R., Porter S.B., Ge Y., June C.H., Blazar B.R., and Boussiotis V.A. CD4+CD25+ regulatory T-cell lines from human cord blood have functional and molecular properties of T-cell anergy. Blood 106 (2005) 3068-3073
105. Liang G., Lin J.C., Wei V., Yoo C., Cheng J.C., Nguyen C.T., Weisenberger D.J., Egger G., Takai D., Gonzales F.A., and Jones P.A. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc. Natl. Acad. Sci. USA 101 (2004) 7357-7362
106. Lomvardas S., and Thanos D. Modifying gene expression programs by altering core promoter chromatin architecture. Cell 110 (2002) 261-271
107. Lugo J.P., Krishnan S.N., Sailor R.D., and Rothenberg E.V. Early precursor thymocytes can produce interleukin 2 upon stimulation with calcium ionophore and phorbol ester. Proc. Natl. Acad. Sci. USA 83 (1986) 1862-1866
108. MacMillan M.L., Radloff G.A., Kiffmeyer W.R., DeFor T.E., Weisdorf D.J., and Davies S.M. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation. Transplantation 76 (2003) 1758-1762
109. Malek T.R. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukoc. Biol. 74 (2003) 961-965
110. Maloy K.J., and Powrie F. Fueling regulation: IL-2 keeps CD4+ Treg cells fit. Nat. Immunol. 6 (2005) 1071-1072
111. Marinari B., Costanzo A., Marzano V., Piccolella E., and Tuosto L. CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters. Proc. Natl. Acad. Sci. USA 101 (2004) 6098-6103
112. Martensson I.L., and Leanderson T. Regulation of interleukin 2 gene expression: Discrepancy between enhancer activity and endogenous gene expression. Eur. J. Immunol. 19 (1989) 145-149
113. Martinez-Campa C., Politis P., Moreau J.L., Kent N., Goodall J., Mellor J., and Goding C.R. Precise nucleosome positioning and the TATA box dictate requirements for the histone H4 tail and the bromodomain factor Bdf1. Mol. Cell 15 (2004) 69-81
114. Matesanz F., Fedetz M., Leyva L., Delgado C., Fernandez O., and Alcina A. Effects of the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic expression. J. Neuroimmunol. 148 (2004) 212-217
115. Matsumoto A., Seki Y., Watanabe R., Hayashi K., Johnston J.A., Harada Y., Abe R., Yoshimura A., and Kubo M. A role of suppressor of cytokine signaling 3 (SOCS3/CIS3/SSI3) in CD28-mediated interleukin 2 production. J. Exp. Med. 197 (2003) 425-436
116. McGuire K.L., and Iacobelli M. Involvement of Rel, Fos, and Jun proteins in binding activity to the IL-2 promoter CD28 response element/AP-1 sequence in human T cells. J. Immunol. 159 (1997) 1319-1327
117. McGuire K.L., Curtiss V.E., Larson E.L., and Haseltine W.A. Influence of human T-cell leukemia virus type I tax and rex on interleukin-2 gene expression. J. Virol. 67 (1993) 1590-1599
118. Michel F., Attal-Bonnefoy G., Mangino G., Mise-Omata S., and Acuto O. CD28 as a molecular amplifier extending TCR ligation and signaling capabilities. Immunity 15 (2001) 935-945
119. Mohr H., Monner D., and Plessing A. Calcium ionophore A 23 187 in the presence of phorbol ester PMA: A potent inducer of interleukin 2 and interferon-gamma synthesis by human blood cells. Immunobiology 171 (1986) 195-204
120. Morgun A., Shulzhenko N., Rampim G.F., Medina J.O., Machado P.G., Diniz R.V., Almeida D.R., and Gerbase-DeLima M. Interleukin-2 gene polymorphism is associated with renal but not cardiac transplant outcome. Transplant. Proc. 35 (2003) 1344-1345
121. Mouzaki A., Serfling E., and Zubler R.H. Interleukin-2 promoter activity in Epstein-Barr virus-transformed B lymphocytes is controlled by nuclear factor-chi B. Eur. J. Immunol. 25 (1995) 2177-2182
122. Munoz E., Zubiaga A., Olson D., and Huber B.T. Control of lymphokine expression in T helper 2 cells. Proc. Natl. Acad. Sci. USA 86 (1989) 9461-9464
123. Murtaza A., Kuchroo V.K., and Freeman G.J. Changes in the strength of co-stimulation through the B7/CD28 pathway alter functional T cell responses to altered peptide ligands. Int. Immunol. 11 (1999) 407-416
124. Niinuma A., Higuchi M., Takahashi M., Oie M., Tanaka Y., Gejyo F., Tanaka N., Sugamura K., Xie L., Green P.L., and Fujii M. Aberrant activation of the interleukin-2 autocrine loop through the nuclear factor of activated T cells by nonleukemogenic human T-cell leukemia virus type 2 but not by leukemogenic type 1 virus. J. Virol. 79 (2005) 11925-11934
125. Novak T.J., and Rothenberg E.V. cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells. Proc. Natl. Acad. Sci. USA 87 (1990) 9353-9357
126. Novak T.J., Chen D., and Rothenberg E.V. Interleukin-1 synergy with phosphoinositide pathway agonists for induction of interleukin-2 gene expression: Molecular basis of costimulation. Mol. Cell. Biol. 10 (1990) 6325-6334
127. Okayama A., Tachibana N., Ishihara S., Nagatomo Y., Murai K., Okamoto M., Shima T., Sagawa K., Tsubouchi H., Stuver S., and Mueller N. Increased expression of interleukin-2 receptor alpha on peripheral blood mononuclear cells in HTLV-I tax/rex mRNA-positive asymptomatic carriers. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 15 (1997) 70-75
128. Oukka M., Wein M.N., and Glimcher L.H. Schnurri-3 (KRC) interacts with c-Jun to regulate the IL-2 gene in T cells. J. Exp. Med. 199 (2004) 15-24
129. Paliogianni F., Raptis A., Ahuja S.S., Najjar S.M., and Boumpas D.T. Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J. Clin. Invest. 91 (1993) 1481-1489
130. Pan F., Ye Z., Cheng L., and Liu J.O. Myocyte enhancer factor 2 mediates calcium-dependent transcription of the interleukin-2 gene in T lymphocytes: A calcium signaling module that is distinct from but collaborates with the nuclear factor of activated T cells (NFAT). J. Biol. Chem. 279 (2004) 14477-14480
131. Parada N.A., Center D.M., Kornfeld H., Rodriguez W.L., Cook J., Vallen M., and Cruikshank W.W. Synergistic activation of CD4+ T cells by IL-16 and IL-2. J. Immunol. 160 (1998) 2115-2120
132. Pawlik A., Kurzawski M., Florczak M., Gawronska Szklarz B., and Herczynska M. IL1beta+3953 exon 5 and IL-2 -330 promoter polymorphisms in patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 23 (2005) 159-164
133. Peters A.H., and Schubeler D. Methylation of histones: Playing memory with DNA. Curr. Opin. Cell. Biol. 17 (2005) 230-238
134. Petitto J.M., Streit W.J., Huang Z., Butfiloski E., and Schiffenbauer J. Interleukin-2 gene deletion produces a robust reduction in susceptibility to experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci. Lett. 285 (2000) 66-70
135. Petrak D., Memon S.A., Birrer M.J., Ashwell J.D., and Zacharchuk C.M. Dominant negative mutant of c-Jun inhibits NF-AT transcriptional activity and prevents IL-2 gene transcription. J. Immunol. 153 (1994) 2046-2051
136. Pfeuffer I., Klein-Hessling S., Heinfling A., Chuvpilo S., Escher C., Brabletz T., Hentsch B., Schwarzenbach H., Matthias P., and Serfling E. Octamer factors exert a dual effect on the IL-2 and IL-4 promoters. J. Immunol. 153 (1994) 5572-5585
137. Postigo A.A., and Dean D.C. ZEB represses transcription through interaction with the corepressor CtBP. Proc. Natl. Acad. Sci. USA 96 (1999) 6683-6688
138. Postigo A.A., and Dean D.C. Differential expression and function of members of the zfh-1 family of zinc finger/homeodomain repressors. Proc. Natl. Acad. Sci. USA 97 (2000) 6391-6396
139. Powell J.D., Ragheb J.A., Kitagawa-Sakakida S., and Schwartz R.H. Molecular regulation of interleukin-2 expression by CD28 co-stimulation and anergy. Immunol. Rev. 165 (1998) 287-300
140. Powell J.D., Lerner C.G., Ewoldt G.R., and Schwartz R.H. The -180 site of the IL-2 promoter is the target of CREB/CREM binding in T cell anergy. J. Immunol. 163 (1999) 6631-6639
141. Radford-Smith G., and Jewell D.P. Cytokines and inflammatory bowel disease. Baillieres Clin. Gastroenterol. 10 (1996) 151-164
142. Rao S., Procko E., and Shannon M.F. Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. J. Immunol. 167 (2001) 4494-4503
143. Rao S., Gerondakis S., Woltring D., and Shannon M.F. c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J. Immunol. 170 (2003) 3724-3731
144. Randak C., Brabletz T., Hergenrother M., Sobotta I., and Serfling E. Cyclosporin A suppresses the expression of the interleukin 2 gene by inhibiting the binding of lymphocyte-specific factors to the IL-2 enhancer. EMBO J. 9 (1990) 2529-2536
145. Reinke H., and Horz W. Histones are first hyperacetylated and then lose contact with the activated PHO5 promoter. Mol. Cell 11 (2003) 1599-1607
146. Reya T., Bassiri H., Biancaniello R., and Carding S.R. Thymic stromal-cell abnormalities and dysregulated T-cell development in IL-2-deficient mice. Dev. Immunol. 5 (1998) 287-302
147. Rincon M., and Flavell R.A. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J. 13 (1994) 4370-4381
148. Rincon M., and Flavell R.A. Regulation of AP-1 and NFAT transcription factors during thymic selection of T cells. Mol. Cell. Biol. 16 (1996) 1074-1084
149. Robertson K.D. DNA methylation and chromatin-unraveling the tangled web. Oncogene 21 (2002) 5361-5379
150. Rodriguez-Galan M.C., Bream J.H., Farr A., and Young H.A. Synergistic effect of IL-2, IL-12, and IL-18 on thymocyte apoptosis and Th1/Th2 cytokine expression. J. Immunol. 174 (2005) 2796-2804
151. Roh T.Y., Cuddapah S., and Zhao K. Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes Dev. 19 (2005) 542-552
152. Romano-Spica V., Georgiou P., Suzuki H., Papas T.S., and Bhat N.K. Role of ETS1 in IL-2 gene expression. J. Immunol. 154 (1995) 2724-2732
153. Rooney J.W., Sun Y.L., Glimcher L.H., and Hoey T. Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation. Mol. Cell. Biol. 15 (1995) 6299-6310
154. Rothenberg E.V., and Ward S.B. A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. Proc. Natl. Acad. Sci. USA 93 (1996) 9358-9365
155. Rothenberg E.V., Diamond R.A., Pepper K.A., and Yang J.A. IL-2 gene inducibility in T cells before T cell receptor expression. Changes in signaling pathways and gene expression requirements during intrathymic maturation. J. Immunol. 144 (1990) 1614-1624
156. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A.C., and Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75 (1993) 253-261
157. Sadlack B., Lohler J., Schorle H., Klebb G., Haber H., Sickel E., Noelle R.J., and Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. 25 (1995) 3053-3059
158. Safford M., Collins S., Lutz M.A., Allen A., Huang C.T., Kowalski J., Blackford A., Horton M.R., Drake C., Schwartz R.H., and Powell J.D. Egr-2 and Egr-3 are negative regulators of T cell activation. Nat. Immunol. 6 (2005) 472-480
159. Santana M.A., and Rosenstein Y. What it takes to become an effector T cell: The process, the cells involved, and the mechanisms. J. Cell. Physiol. 195 (2003) 392-401
160. Sassone-Corsi P. Coupling gene expression to cAMP signalling: Role of CREB and CREM. Int. J. Biochem. Cell Biol. 30 (1998) 27-38
161. Savignac M., Pintado B., Gutierrez-Adan A., Palczewska M., Mellstrom B., and Naranjo J.R. Transcriptional repressor DREAM regulates T-lymphocyte proliferation and cytokine gene expression. EMBO J. 24 (2005) 3555-3564
162. Schimpl A., Berberich I., Kneitz B., Kramer S., Santner-Nanan B., Wagner S., Wolf M., and Hunig T. IL-2 and autoimmune disease. Cytokine Growth Factor Rev. 13 (2002) 369-378
163. Schorle H., Holtschke T., Hunig T., Schimpl A., and Horak I. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352 (1991) 621-624
164. Schule R., Rangarajan P., Kliewer S., Ransone L.J., Bolado J., Yang N., Verma I.M., and Evans R.M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell 62 (1990) 1217-1226
165. Schwartz R.H. T cell anergy. Annu. Rev. Immunol. 21 (2003) 305-334
166. Schwarz M.J., Kronig H., Riedel M., Dehning S., Douhet A., Spellmann I., Ackenheil M., Moller H.J., and Muller N. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 256 (2006) 72-76
167. Sedwick C.E., and Altman A. Perspectives on PKCtheta in T cell activation. Mol. Immunol. 41 (2004) 675-686
168. Serfling E., Avots A., and Neumann M. The architecture of the interleukin-2 promoter: A reflection of T lymphocyte activation. Biochim. Biophys. Acta 1263 (1995) 181-200
169. Shannon M.F., Himes S.R., and Attema J. A role for the architectural transcription factors HMGI(Y) in cytokine gene transcription in T cells. Immunol. Cell Biol. 76 (1998) 461-466
170. Shannon M.F., Coles L.S., Attema J., and Diamond P. The role of architectural transcription factors in cytokine gene transcription. J. Leukoc. Biol. 69 (2001) 21-32
171. Shapiro V.S., Mollenauer M.N., Greene W.C., and Weiss A. c-rel regulation of IL-2 gene expression may be mediated through activation of AP-1. J. Exp. Med. 184 (1996) 1663-1669
172. Shapiro V.S., Truitt K.E., Imboden J.B., and Weiss A. CD28 mediates transcriptional upregulation of the interleukin-2 (IL-2) promoter through a composite element containing the CD28RE and NF-IL-2B AP-1 sites. Mol. Cell. Biol. 17 (1997) 4051-4058
173. Shapiro V.S., Mollenauer M.N., and Weiss A. Nuclear factor of activated T cells and AP-1 are insufficient for IL-2 promoter activation: Requirement for CD28 up-regulation of RE/AP. J. Immunol. 161 (1998) 6455-6458
174. Shaw J.P., Utz P.J., Durand D.B., Toole J.J., Emmel E.A., and Crabtree G.R. Identification of a putative regulator of early T cell activation genes. Science 241 (1988) 202-205
175. Shi Y., Sawada J., Sui G., Affar el B., Whetstine J.R., Lan F., Ogawa H., Luke M.P., and Nakatani Y. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 422 (2003) 735-738
176. Shibuya H., and Taniguchi T. Identification of multiple cis-elements and trans-acting factors involved in the induced expression of human IL-2 gene. Nucleic Acids Res. 17 (1989) 9173-9184
177. Siebenlist U., Durand D.B., Bressler P., Holbrook N.J., Norris C.A., Kamoun M., Kant J.A., and Crabtree G.R. Promoter region of interleukin-2 gene undergoes chromatin structure changes and confers inducibility on chloramphenicol acetyltransferase gene during activation of T cells. Mol. Cell. Biol. 6 (1986) 3042-3049
178. Siefken R., Kurrle R., and Schwinzer R. CD28-mediated activation of resting human T cells without costimulation of the CD3/TCR complex. Cell. Immunol. 176 (1997) 59-65
179. Skerka C., Decker E.L., and Zipfel P.F. A regulatory element in the human interleukin 2 gene promoter is a binding site for the zinc finger proteins Sp1 and EGR-1. J. Biol. Chem. 270 (1995) 22500-22506
180. Smith J.L., Collins I., Chandramouli G.V., Butscher W.G., Zaitseva E., Freebern W.J., Haggerty C.M., Doseeva V., and Gardner K. Targeting combinatorial transcriptional complex assembly at specific modules within the interleukin-2 promoter by the immunosuppressant SB203580. J. Biol. Chem. 278 (2003) 41034-41046
181. Smith J.L., Freebern W.J., Collins I., De Siervi A., Montano I., Haggerty C.M., McNutt M.C., Butscher W.G., Dzekunova I., Petersen D.W., Kawasaki E., Merchant J.L., et al. Kinetic profiles of p300 occupancy in vivo predict common features of promoter structure and coactivator recruitment. Proc. Natl. Acad. Sci. USA 101 (2004) 11554-11559
182. Solomou E.E., Juang Y.T., and Tsokos G.C. Protein kinase C-theta participates in the activation of cyclic AMP-responsive element-binding protein and its subsequent binding to the -180 site of the IL-2 promoter in normal human T lymphocytes. J. Immunol. 166 (2001) 5665-5674
183. Stopka T., Amanatullah D.F., Papetti M., and Skoultchi A.I. PU.1 inhibits the erythroid program by binding to GATA-1 on DNA and creating a repressive chromatin structure. EMBO J. 24 (2005) 3712-3723
184. Su L., Creusot R.J., Gallo E.M., Chan S.M., Utz P.J., Fathman C.G., and Ermann J. Murine CD4+CD25+ regulatory T cells fail to undergo chromatin remodeling across the proximal promoter region of the IL-2 gene. J. Immunol. 173 (2004) 4994-5001
185. Sundstrom S., Ota S., Dimberg L.Y., Masucci M.G., and Bergqvist A. Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses. J. Virol. 79 (2005) 2230-2239
186. Suzuki H., Kundig T.M., Furlonger C., Wakeham A., Timms E., Matsuyama T., Schmits R., Simard J.J., Ohashi P.S., Griesser H., Taniguchi T., Paige C.J., et al. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 268 (1995) 1472-1476
187. Taniguchi T., Matsui H., Fujita T., Takaoka C., Kashima N., Yoshimoto R., and Hamuro J. Structure and expression of a cloned cDNA for human interleukin-2. Nature 302 (1983) 305-310
188. Tenbrock K., and Tsokos G.C. Transcriptional regulation of interleukin 2 in SLE T cells. Int. Rev. Immunol. 23 (2004) 333-345
189. Tenbrock K., Juang Y.T., Gourley M.F., Nambiar M.P., and Tsokos G.C. Antisense cyclic adenosine 5′-monophosphate response element modulator up-regulates IL-2 in T cells from patients with systemic lupus erythematosus. J. Immunol. 169 (2002) 4147-4152
190. Tenbrock K., Juang Y.T., Tolnay M., and Tsokos G.C. The cyclic adenosine 5′-monophosphate response element modulator suppresses IL-2 production in stimulated T cells by a chromatin-dependent mechanism. J. Immunol. 170 (2003) 2971-2976
191. Thomas R.M., Gao L., and Wells A.D. Signals from CD28 induce stable epigenetic modification of the IL-2 promoter. J. Immunol. 174 (2005) 4639-4646
192. Thompson C.B., Wang C.Y., Ho I.C., Bohjanen P.R., Petryniak B., June C.H., Miesfeldt S., Zhang L., Nabel G.J., Karpinski B., and Leiden J.M. cis-acting sequences required for inducible interleukin-2 enhancer function bind a novel Ets-related protein, Elf-1. Mol. Cell. Biol. 12 (1992) 1043-1053
193. Togawa S., Joh T., Itoh M., Katsuda N., Ito H., Matsuo K., Tajima K., and Hamajima N. Interleukin-2 gene polymorphisms associated with increased risk of gastric atrophy from Helicobacter pylori infection. Helicobacter. 10 (2005) 172-178
194. Tsuda H., Huang R.W., and Takatsuki K. Interleukin-2 prevents programmed cell death in adult T-cell leukemia cells. Jpn. J. Cancer Res. 84 (1993) 431-437
195. Verweij C.L., Geerts M., and Aarden L.A. Activation of interleukin-2 gene transcription via the T-cell surface molecule CD28 is mediated through an NF-kB-like response element. J. Biol. Chem. 266 (1991) 14179-14182
196. Wang H., Diamond R.A., Yang-Snyder J.A., and Rothenberg E.V. Precocious expression of T cell functional response genes in vivo in primitive thymocytes before T lineage commitment. Int. Immunol. 10 (1998) 1623-1635
197. Wang L., Kametani Y., Katano I., and Habu S. T-cell specific enhancement of histone H3 acetylation in 5′ flanking region of the IL-2 gene. Biochem. Biophys. Res. Commun. 331 (2005) 589-594
198. Wang W., Tam W.F., Hughes C.C., Rath S., and Sen R. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation. Immunity 6 (1997) 165-174
199. Ward S.B., Hernandez-Hoyos G., Chen F., Waterman M., Reeves R., and Rothenberg E.V. Chromatin remodeling of the interleukin-2 gene: Distinct alterations in the proximal versus distal enhancer regions. Nucleic Acids Res. 26 (1998) 2923-2934
200. Wieland G.D., Nehmann N., Muller D., Eibel H., Siebenlist U., Suhnel J., Zipfel P.F., and Skerka C. Early growth response proteins EGR-4 and EGR-3 interact with immune inflammatory mediators NF-kappaB p50 and p65. J. Cell. Sci. 118 (2005) 3203-3212
201. Willerford D.M., Chen J., Ferry J.A., Davidson L., Ma A., and Alt F.W. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3 (1995) 521-530
202. Williams T.M., Moolten D., Burlein J., Romano J., Bhaerman R., Godillot A., Mellon M., Rauscher III F.J., and Kant J.A. Identification of a zinc finger protein that inhibits IL-2 gene expression. Science 254 (1991) 1791-1794
203. Wong H.K., Kammer G.M., Dennis G., and Tsokos G.C. Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J. Immunol. 163 (1999) 1682-1689
204. Wu J., and Lingrel J.B. Kruppel-like factor 2, a novel immediate-early transcriptional factor, regulates IL-2 expression in T lymphocyte activation. J. Immunol. 175 (2005) 3060-3066
205. Yang-Snyder J.A., and Rothenberg E.V. Developmental and anatomical patterns of IL-2 gene expression in vivo in the murine thymus. Dev. Immunol. 3 (1993) 85-102
206. Yao T.P., Oh S.P., Fuchs M., Zhou N.D., Ch'ng L.E., Newsome D., Bronson R.T., Li E., Livingston D.M., and Eckner R. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 93 (1998) 361-372
207. Yaseen N.R., Park J., Kerppola T., Curran T., and Sharma S. A central role for Fos in human B- and T-cell NFAT (nuclear factor of activated T cells): An acidic region is required for in vitro assembly. Mol. Cell. Biol. 14 (1994) 6886-6895
208. Yasui D.H., Genetta T., Kadesch T., Williams T.M., Swain S.L., Tsui L.V., and Huber B.T. Transcriptional repression of the IL-2 gene in Th cells by ZEB. J. Immunol. 160 (1998) 4433-4440
209. Yie J., Merika M., Munshi N., Chen G., and Thanos D. The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J. 18 (1999) 3074-3089
210. Yui M.A., Hernandez-Hoyos G., and Rothenberg E.V. A new regulatory region of the IL-2 locus that confers position-independent transgene expression. J. Immunol. 166 (2001) 1730-1739
211. Yui M.A., Sharp L.L., Havran W.L., and Rothenberg E.V. Preferential activation of an IL-2 regulatory sequence transgene in TCR gamma delta and NKT cells: Subset-specific differences in IL-2 regulation. J. Immunol. 172 (2004) 4691-4699
212. Zhang L., and Nabel G.J. Positive and negative regulation of IL-2 gene expression: Role of multiple regulatory sites. Cytokine 6 (1994) 221-228
213. Zhao G., Shi L., Qiu D., Hu H., and Kao P.N. NF45/ILF2 tissue expression, promoter analysis, and interleukin-2 transactivating function. Exp. Cell. Res. 305 (2005) 312-323
214. Zhou X.Y., Yashiro-Ohtani Y., Nakahira M., Park W.R., Abe R., Hamaoka T., Naramura M., Gu H., and Fujiwara H. Molecular mechanisms underlying differential contribution of CD28 versus non-CD28 costimulatory molecules to IL-2 promoter activation. J. Immunol. 168 (2002) 3847-3854
215. Zubiaga A.M., Munoz E., and Huber B.T. Superinduction of IL-2 gene transcription in the presence of cycloheximide. J. Immunol. 146 (1991) 3857-3863